Pharmaessentia

Pharmaessentia company information, Employees & Contact Information

Explore related pages

Related company profiles:

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology, and immunology. Founded in 2003, PharmaEssentia is now expanding its global presence with operations in the U.S., Japan, China and Korea.

Company Details

Employees
310
Founded
-
Address
35 Corporate Drive, Suite 325,taiwan, Province Of China
Phone
+886-2-2655-7688
Email
in****@****tia.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Burlington, MA
Looking for a particular Pharmaessentia employee's phone or email?

Pharmaessentia Questions

News

PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire

PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference Business Wire

PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting - Yahoo Finance

PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting Yahoo Finance

PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms - Business Wire

PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms Business Wire

PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting - Business Wire

PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting Business Wire

With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi - Fierce Pharma

With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi Fierce Pharma

Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b - Wiley Online Library

Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b Wiley Online Library

GLOBAL BIOPHARMACEUTICAL INNOVATOR PHARMAESSENTIA LAUNCHES NEW TREATMENT BESREMi®️ FOR RARE BLOOD CANCER IN SINGAPORE - PR Newswire

GLOBAL BIOPHARMACEUTICAL INNOVATOR PHARMAESSENTIA LAUNCHES NEW TREATMENT BESREMi®️ FOR RARE BLOOD CANCER IN SINGAPORE PR Newswire

CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical - The AI Journal

CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical The AI Journal

ASCO25: PharmaEssentia's Besremi hits mark in late-stage thrombocythaemia study - FirstWord Pharma

ASCO25: PharmaEssentia's Besremi hits mark in late-stage thrombocythaemia study FirstWord Pharma

CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia - Business Wire

CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia Business Wire

BPS Publications - British Pharmacological Society | Journals

BPS Publications British Pharmacological Society | Journals

PharmaEssentia nabs MorphoSys GM Horvat to lead its commercial team - Fierce Pharma

PharmaEssentia nabs MorphoSys GM Horvat to lead its commercial team Fierce Pharma

(ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys - Business Wire

(ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys Business Wire

PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer - Business Wire

PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer Business Wire

PharmaEssentia Appoints Beth A. Krewson as Head of Legal - Business Wire

PharmaEssentia Appoints Beth A. Krewson as Head of Legal Business Wire

PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi - Business Wire

PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi Business Wire

PharmaEssentia Establishes a New Research and Development Facility in the Boston Area - Business Wire

PharmaEssentia Establishes a New Research and Development Facility in the Boston Area Business Wire

PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas - Business Wire

PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas Business Wire

NCCN Lists Ropeginterferon Alfa-2B As Preferred First-Line Cytoreductive Therapy for Polycythemia Vera - OncLive

NCCN Lists Ropeginterferon Alfa-2B As Preferred First-Line Cytoreductive Therapy for Polycythemia Vera OncLive

Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b - Frontiers

Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b Frontiers

ECLIPSE PV Trial Begins Ropeginterferon Alfa-2b Dosing in Polycythemia Vera - OncLive

ECLIPSE PV Trial Begins Ropeginterferon Alfa-2b Dosing in Polycythemia Vera OncLive

Taiwan Pavilion Fostering Collaborative Innovation in AI, Regenerative Medicine and CDMO at BioJapan 2025 - Laotian Times

Taiwan Pavilion Fostering Collaborative Innovation in AI, Regenerative Medicine and CDMO at BioJapan 2025 Laotian Times

Transformation: PharmaEssentia sees IPO as best way for research-and-development-focused organisation to become a bona fide operational and marketing firm - South China Morning Post

Transformation: PharmaEssentia sees IPO as best way for research-and-development-focused organisation to become a bona fide operational and marketing firm South China Morning Post

PharmaEssentia and AOP Orphan Receive EU Approval of Besremi™ (Ropeginterferon Alfa-2b) for Treatment of Polycythemia Vera (PV) in EU - NAI500

PharmaEssentia and AOP Orphan Receive EU Approval of Besremi™ (Ropeginterferon Alfa-2b) for Treatment of Polycythemia Vera (PV) in EU NAI500

Top Pharmaessentia Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant